KCP
ELDN icon

Kera Capital Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Kera Capital Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123K Buy
39,908
+138
+0.3% +$325 0.02% 558
2025
Q4 		$87.5K Buy
39,770
+14,000
+54% +$33.3K 0.01% 544
2025
Q3 		$66.7K Hold
25,770
– – 0.01% 414
2025
Q2 		$69.8K Hold
25,770
– – 0.01% 346
2025
Q1 		$87.4K Hold
25,770
– – 0.03% 183
2024
Q4 		$106K Buy
+25,770
New +$102K 0.03% 153

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Kera Capital Partners's ELDN Position: Q1 2026 in Review

Kera Capital Partners increased its Eledon Pharmaceuticals (ELDN) stake by 0.35% in Q1 2026, buying an estimated $325 and bringing the position to 39,908 shares worth $123K. The position accounts for 0.02% of the portfolio, ranked #558.

Kera Capital Partners first reported a position in ELDN in Q4 2024 and has held it in 6 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Kera Capital Partners held 39,908 shares of Eledon Pharmaceuticals worth $123K as of Q1 2026.
  • Kera Capital Partners bought 138 Eledon Pharmaceuticals shares in Q1 2026, an estimated $325.
  • Eledon Pharmaceuticals made up 0.02% of Kera Capital Partners's portfolio in Q1 2026, its #558 holding.
  • Kera Capital Partners first reported a position in Eledon Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Kera Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.